IL186286A0 - Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions - Google Patents
Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditionsInfo
- Publication number
- IL186286A0 IL186286A0 IL186286A IL18628607A IL186286A0 IL 186286 A0 IL186286 A0 IL 186286A0 IL 186286 A IL186286 A IL 186286A IL 18628607 A IL18628607 A IL 18628607A IL 186286 A0 IL186286 A0 IL 186286A0
- Authority
- IL
- Israel
- Prior art keywords
- calcitonin
- management
- inflammatory disease
- combined treatment
- disease conditions
- Prior art date
Links
- 102000055006 Calcitonin Human genes 0.000 title 1
- 108060001064 Calcitonin Proteins 0.000 title 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title 1
- 229960004015 calcitonin Drugs 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0506708.7A GB0506708D0 (en) | 2005-04-01 | 2005-04-01 | Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions |
| PCT/GB2006/001183 WO2006103455A2 (en) | 2005-04-01 | 2006-03-30 | Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL186286A0 true IL186286A0 (en) | 2008-01-20 |
Family
ID=34586589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL186286A IL186286A0 (en) | 2005-04-01 | 2007-09-25 | Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080160025A1 (enExample) |
| EP (1) | EP1868627B1 (enExample) |
| JP (2) | JP2008534566A (enExample) |
| KR (1) | KR20080017001A (enExample) |
| CN (1) | CN101180070A (enExample) |
| AU (1) | AU2006228334A1 (enExample) |
| BR (1) | BRPI0612220A2 (enExample) |
| CA (1) | CA2603156A1 (enExample) |
| GB (1) | GB0506708D0 (enExample) |
| IL (1) | IL186286A0 (enExample) |
| MX (1) | MX2007012078A (enExample) |
| RU (1) | RU2394591C2 (enExample) |
| WO (1) | WO2006103455A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012040364A1 (en) | 2010-09-21 | 2012-03-29 | Unigene Laboratories Inc. | Calcitonin products and therapies for treating inflammatory or degenerative diseases |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| US9616081B2 (en) * | 2013-03-27 | 2017-04-11 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent including low-dose irinotecan hydrochloride hydrate |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4006269A1 (de) * | 1990-02-28 | 1991-08-29 | Max Planck Gesellschaft | Antikoerper gegen den tumor-nekrosefaktor-rezeptor |
| UA41909C2 (uk) * | 1994-07-22 | 2001-10-15 | Елі Ліллі Енд Компані | Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат |
| WO2001013957A2 (en) * | 1999-08-24 | 2001-03-01 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| US20060002935A1 (en) * | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| WO2005009949A2 (en) * | 2003-06-30 | 2005-02-03 | Merck & Co., Inc. | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
-
2005
- 2005-04-01 GB GBGB0506708.7A patent/GB0506708D0/en not_active Ceased
-
2006
- 2006-03-30 JP JP2008503594A patent/JP2008534566A/ja not_active Withdrawn
- 2006-03-30 US US11/910,023 patent/US20080160025A1/en not_active Abandoned
- 2006-03-30 EP EP06726589.2A patent/EP1868627B1/en not_active Expired - Lifetime
- 2006-03-30 BR BRPI0612220-5A patent/BRPI0612220A2/pt not_active IP Right Cessation
- 2006-03-30 AU AU2006228334A patent/AU2006228334A1/en not_active Abandoned
- 2006-03-30 CA CA002603156A patent/CA2603156A1/en not_active Abandoned
- 2006-03-30 RU RU2007139888/15A patent/RU2394591C2/ru not_active IP Right Cessation
- 2006-03-30 MX MX2007012078A patent/MX2007012078A/es active IP Right Grant
- 2006-03-30 CN CNA2006800137667A patent/CN101180070A/zh active Pending
- 2006-03-30 KR KR1020077025348A patent/KR20080017001A/ko not_active Ceased
- 2006-03-30 WO PCT/GB2006/001183 patent/WO2006103455A2/en not_active Ceased
-
2007
- 2007-09-25 IL IL186286A patent/IL186286A0/en unknown
-
2012
- 2012-09-13 JP JP2012201476A patent/JP2013032360A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2603156A1 (en) | 2006-10-05 |
| JP2013032360A (ja) | 2013-02-14 |
| JP2008534566A (ja) | 2008-08-28 |
| BRPI0612220A2 (pt) | 2010-10-26 |
| RU2394591C2 (ru) | 2010-07-20 |
| MX2007012078A (es) | 2008-02-22 |
| EP1868627A2 (en) | 2007-12-26 |
| CN101180070A (zh) | 2008-05-14 |
| WO2006103455A3 (en) | 2007-03-01 |
| KR20080017001A (ko) | 2008-02-25 |
| WO2006103455A2 (en) | 2006-10-05 |
| US20080160025A1 (en) | 2008-07-03 |
| EP1868627B1 (en) | 2014-10-15 |
| RU2007139888A (ru) | 2009-05-10 |
| GB0506708D0 (en) | 2005-05-11 |
| AU2006228334A1 (en) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200707591B (en) | Dihyrothienopyrimidines for the treatment of inflammatory diseases | |
| IL194076A0 (en) | Imidazolothiazole compounds for the treatment of disease | |
| EP1976377A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| ZA200803440B (en) | Compounds for the treatment of metabolic disorders | |
| EP1983972A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| IL195203A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL192852A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL200091A0 (en) | Use of chitosans for the treatment of nail inflammatory diseases | |
| GB0410399D0 (en) | The treatment of respiratory disease | |
| GB0700972D0 (en) | Treatment of inflammatory disease | |
| GB0410398D0 (en) | The treatment of respiratory disease | |
| GB0720976D0 (en) | Treatment of inflammatory disease | |
| PL1945243T3 (pl) | Zastosowanie kalcytoniny w leczeniu rzs | |
| IL195392A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL192851A0 (en) | Compounds for the treatment of metabolic disorders | |
| GB0400802D0 (en) | Compounds for the treatment of disease | |
| GB0506708D0 (en) | Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions | |
| HU0500145D0 (en) | Composition for the treatment of oral diseases | |
| GB0428218D0 (en) | Medicament for Treatment of Inflammatory Diseases | |
| ZA200606780B (en) | Compounds for the treatment of diseases | |
| IL192982A0 (en) | Compounds for the treatment of metabolic disorders | |
| GB0411301D0 (en) | Treatment of inflammatory disease | |
| GB0415352D0 (en) | Compounds for the treatment of disease | |
| GB0420867D0 (en) | Compounds for the treatment of diseases | |
| GB0425073D0 (en) | Compounds for the treatment of diseases |